Among the large drugmakers, Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer are worth retaining in one’s portfolio.

GSK, Sanofi and CSL Ltd have secured $72 million from the US government to ramp up production of bird flu vaccines, Reuters ...

Kymera Therapeutics is a biotech company with innovative technology targeting disease-causing proteins, offering promising ...

We recently compiled a list of the 7 Best Under The Radar Stocks to Buy According to Analysts. In this article, we are going ...

Recordati will acquire global rights to Enjaymo from Sanofi for $825M, boosting its rare disease portfolio. The deal includes ...

Novavax's financial position improved significantly with a $570 million cash infusion from Sanofi. Find out why I remain ...

The FDA approved Regeneron and Sanofi's Dupixent as an add-on treatment for inadequately controlled COPD, demonstrating ...

The drug and biotech sector has outperformed the broader equity market this year, backed by the launch of promising new ...

Value investors will likely look at more than just these metrics, but the above data helps show that Sanofi is likely undervalued currently. And when considering the strength of its earnings outlook, ...

Bank of America Securities analyst Graham Parry maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target ...

Analyst Eric Le Berrigaud from Stifel Nicolaus maintained a Buy rating on Sanofi (SNYNF – Research Report) and increased the price target ...